Vitamin D3 seems more appropriate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach

Background/Objectives: The superiority of cholecalciferol (D 3 ) over ergocalciferol (D 2 ) in sustaining serum 25-hydroxy vitamin D (25OHD) levels is controversial. To compare D 2 with D 3 we performed a single-blind, placebo-controlled randomized trial spanning 11 weeks. Subjects/Methods: Healthy...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical nutrition 2015-06, Vol.69 (6), p.697-702
Main Authors: Oliveri, B, Mastaglia, S R, Brito, G M, Seijo, M, Keller, G A, Somoza, J, Diez, R A, Di Girolamo, G
Format: Article
Language:English
Subjects:
25-Hydroxyvitamin D 2 - blood
631/154/436/1729
631/443/810
692/700/565/2072
Adult
Argentina
Calcifediol - blood
Calciferol
Calcium - blood
Calcium - urine
Cholecalciferol - adverse effects
Cholecalciferol - metabolism
Cholecalciferol - therapeutic use
Clinical Nutrition
Concentration time
Dietary supplements
Dietary Supplements - adverse effects
Drug therapy
Epidemiology
Ergocalciferols - adverse effects
Ergocalciferols - metabolism
Ergocalciferols - therapeutic use
Female
Follow-Up Studies
Half-Life
Health aspects
Hospitals, University
Hospitals, Urban
Humans
Internal Medicine
Kinetics
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Models, Biological
Nutrition
original-article
Personnel, Hospital
Pharmacokinetics
Public Health
Single-Blind Method
Supplements
Vitamin D
Vitamin D Deficiency - blood
Vitamin D Deficiency - prevention & control
Vitamin D Deficiency - urine
Vitamin D3
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Objectives: The superiority of cholecalciferol (D 3 ) over ergocalciferol (D 2 ) in sustaining serum 25-hydroxy vitamin D (25OHD) levels is controversial. To compare D 2 with D 3 we performed a single-blind, placebo-controlled randomized trial spanning 11 weeks. Subjects/Methods: Healthy volunteers ( n =33, aged 33.4±6 years) were divided into three groups ( n =11, each): D 2 , D 3 and placebo. Treatment started with a loading dose (100 000 IU) followed by 4800 IU/day (d) between d7 and d20 and follow-up until d77. Serum samples were obtained at baseline and at days 3, 7, 14, 21, 35, 49, 63 and 77. Results: Baseline 25OHD values in the D 2 group were lower than those in the D 3 and placebo groups ( P
ISSN:0954-3007
1476-5640
DOI:10.1038/ejcn.2015.16